High Growth Tech Stocks to Watch in October 2024

In This Article:

The United States market has experienced a flat performance over the past week, although it has risen by 37% over the last 12 months, with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks involves focusing on companies that demonstrate strong innovation and adaptability to capitalize on these favorable market conditions.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

21.08%

28.73%

★★★★★★

Sarepta Therapeutics

23.83%

44.09%

★★★★★★

TG Therapeutics

28.39%

43.54%

★★★★★★

Invivyd

42.91%

70.39%

★★★★★★

Ardelyx

27.19%

66.44%

★★★★★★

Amicus Therapeutics

20.33%

62.45%

★★★★★★

AsiaFIN Holdings

60.53%

81.55%

★★★★★★

Travere Therapeutics

29.24%

70.32%

★★★★★★

Seagen

22.57%

71.80%

★★★★★★

ImmunoGen

26.00%

45.85%

★★★★★★

Click here to see the full list of 250 stocks from our US High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Akebia Therapeutics

Simply Wall St Growth Rating: ★★★★★☆

Overview: Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutics for kidney disease patients, with a market cap of approximately $288.09 million.

Operations: The company generates revenue primarily from developing and commercializing novel therapeutics for kidney disease, amounting to $174.50 million.

Akebia Therapeutics, despite being unprofitable, is navigating a promising trajectory with expected revenue growth of 24.4% annually, surpassing the US market average of 8.8%. This growth is complemented by an aggressive R&D strategy, where expenses are tightly aligned with innovation in treatments for chronic kidney disease (CKD). Recently approved by the FDA, Vafseo® marks a significant milestone and is set to be commercially available in January 2025. The company's recent contract with U.S. Renal Care underscores its strategic positioning within the nephrology sector, potentially enhancing its market presence upon Vafseo’s launch. Moreover, Akebia's commitment to advancing CKD treatment was evident at ASN Kidney Week 2024, where it presented promising data on vadadustat’s safety and efficacy. These developments suggest a robust framework for future growth and industry contribution despite current financial losses and high share price volatility.

NasdaqCM:AKBA Revenue and Expenses Breakdown as at Oct 2024
NasdaqCM:AKBA Revenue and Expenses Breakdown as at Oct 2024

Bilibili

Simply Wall St Growth Rating: ★★★★☆☆